Aranespti is a 165amino acid protein that differs from recombinant human erythropoietin in containing 5 nlinked oligosaccharide. Capitals indicate lifethreatening, underlines indicate most frequent. Epo, also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidney in response to cellular hypoxia. History of erythropoiesisstimulating agents, the development of. Arterial hypertension induced by erythropoietin and erythropoiesisstimulating agents esa reto krapf, henry n. Esas are biologically engineered hormones produced by recombinant dna technology. Pdf erythropoietin stimulating agents in the management. Reimbursement policy erythropoietin stimulating agent esa level of less than 500 muml are more likely to respond to erythropoiesisstimulating agent esa therapy. Erythropoiesis stimulating agents and other growth factors.
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Types of erythropoietinstimulating agents and mortality. Food and drug administration fda and amgen notified healthcare professionals and patients that all erythropoiesisstimulating agents esas must be used under a risk evaluation and mitigation strategy rems risk management program. Who eml 20162017 erythropoietinstimulating agents december 2016. Erythropoietinstimulating agents erythropoietin epo is produced by the kidney and used to make red blood cells. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease article pdf available in patient preference and adherence 2. It is produced by cloning the gene for erythropoietin. Lack of objective benefit of normalizing hemoglobin hb levels and increased evidence of esainduced complications in persons with anemia has resulted in clinicians generally attempting to. Reimbursement policy erythropoietin stimulating agent esa. This policy addresses the following erythropoiesisstimulating agents esas. Epoetin alfa and darbepoetin alfa are erythropoiesisstimulating agents esas, approved for the treatment of anemia low red blood cells resulting from chronic kidney disease, chemotherapy.
Patients receiving zidovudine with endogenous serum erythropoietin levels 500 munitsml may not respond. Epo is a protein hormone 165 amino acids primarily synthesized by the kidneys that contains 3 n glycan and 1 o glycan side chain. An erythropoietin stimulating agent esa is an analog of erythropoietin. Information on erythropoiesisstimulating agents esa. Erythropoiesisstimulating agents prices and information.
Erythropoiesisstimulating agents esas have been implicated in causing cancer progression. The efficacy of erythropoietinstimulating agents esas for improving healthrelated quality of life hrqol in anemia of chronic kidney disease ckd is unclear. Effective april 1, 2006 pdf chapter 11 end stage renal disease esrd pdf chapter 8 outpatient esrd hospital, independent facility, and physiciansupplier claims pdf. Chronic kidney diseaseerythropoiesisstimulating agentsbiosimilar. Erythropoiesisstimulating agents page 1 of 14 unitedhealthcare commercial medical benefit drug policy effective 01012020. The data considered at this meeting included a mix of published studies, summary results from closed studies provided to the us fda by the sponsors or others, and primary data from closed studies data provided to the us.
Dosing, uses, side effects, interactions, patient handouts, pricing and more from medscape reference. Erythropoietin epo is an approved drug that is used in the treatment of chronic anemia associated with chronic renal failure. Erythropoiesis stimulating agents 2 high risk for perioperative transfusions with significant, anticipated blood loss, for example, for patients expected to lose greater than two units of blood. The median duration of response is 23 years, with patients responding for more than a decade. Erythropoietin and erythropoiesis stimulating agents. More recent trials using esa doses with hgb targets similar to current goal levels in ckd have not confirmed this increased risk of. Treatment with erythropoiesisstimulating agents esas is firstline treatment for the anemia of most patients with mds. Aranesp darbepoetin alfa, also known as novel erythropoiesis stimulating protein nesp, is an erythropoiesis stimulating protein closely related to erythropoietin that is produced in chinese hamster ovary cells by recombinant dna technology. Anemia secondary to myelodysplastic syndrome mds o treatment of lower risk disease associated with symptomatic anemia.
Esa monitoring policy, effective october 1, 2006 pdf. January 1, 2020 page 2 of 6 aranesp is covered for the following indications. Allan2,3,4, and anargyros xenocostas1,2,4,5 abstract over the past few decades, understanding of the physiologic function of. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in hivaids. The erythropoiesisstimulating agents esas currently available are darbepoetin alfa aranesp, epoetin alfa epogen. Erythropoetinstimulating agents are used often for people with longterm kidney disease and anemia. Recombinant erythropoietin drugs are known as erythropoietinstimulating agents esas. In these situations they decrease the need for blood transfusions. The role of erythropoietin and erythropoiesisstimulating. Cms has policies that effect the use of erythropoietin stimulating agents in esrd facilities. The safety of erythropoiesisstimulating agents in cancer. Therapeutic class overview erythropoiesisstimulating agents therapeutic class overviewsummary.
Erythropoietin stimulating agents are similar to erythropoietin, as it stimulates the growth of red blood cells. More recent trials using esa doses with hgb targets similar to current goal levels in ckd have not confirmed this increased. Endogenous erythropoietin is a glycoprotein hematopoietic growth factor that regulates hemoglobin levels in response to changes in the blood oxygen concentration. Erythropoietinstimulating agents in anemia of chronic. In the neuro icu, there are two potential uses for treatment with epo. Erythropoiesis stimulating agents esas this article contains instructions for coding medical necessity in accordance with both the national coverage determination ncd and local coverage determination lcd and other cms instructions on darbepoetin alfa aranesp. Esas have been approved for the treatment of anemia, due to chronic kidney failure, chemotherapy, hiv, and also for reduced red blood cells. They were initially developed as replacement therapy to treat anemia due to endogenous erythropoietin deficiency that commonly occurs in individuals with chronic renal failure crf secondary to ckd. Erythropoiesis stimulating agents esas are abused by athletes because they increase the oxygencarrying capacity of the blood by stimulating red blood cell production 25. Erythropoiesisstimulating agents are used to treat anemia and kidney disease. Background despite the widespread use of erythropoietinstimulating agents esas to treat anemia in patients undergoing hemodialysis, the relative mortality.
The treatment was highly effective, but because of the fairly short halflife of the molecule at approximately 6 to 8 h. These drugs are given by injection shot and work by stimulating the production of more red blood cells. Erythropoiesis stimulating agents esa includes the following products. Aetna medicare form erythropoiesis stimulating agents. Erythropoietin stimulating agents market growth, trends. To determine the effect of esas on hrqol at different hemoglobin targets in adults with ckd who were receiving or not receiving dialysis. Erythropoietin stimulating agents esas 3 erythropoietin directly and other causes of anemia have been ruled out.
Erythropoietin acts synergistically with gcsf to inhibit erythroid apoptosis and promote erythrocyte production. The role of erythropoietin and erythropoiesisstimulating agents in tumor progression benjamin d. There is a lack of relliable evidence that one brand of erythropoietin alpha procrit or epogen. Erythropoiesisstimulating agents esas came into widespread use after they became available in the late 1990s, especially in the metastatic cancer setting. Further increases may be made at 4week intervals until the specified hemoglobin is obtained. Erythropoiesis stimulating agents esa are considered experimental, investigational or unproven for any other indication including the following. Erythropoiesisstimulating agents esas are effective drugs that correct and maintain haemoglobin hb at an appropriate level in the majority of anaemic patients with chronic kidney disease ckd, thus reducing fatigue, increasing quality of life and decreasing the need for blood transfusions.
Recombinant erythropoietin is a manmade version of natural erythropoietin. Nearly two decades ago, recombinant human erythropoietin transformed the management of chronic kidney disease anemia by allowing a more sustained increase in hemoglobin than was possible by intermittent blood transfusion. Arterial hypertension induced by erythropoietin and. Hyporesponsiveness to erythropoietin stimulating agents occurs frequently, and may be observed at initiation of treatment or during maintenance therapy. This belief has been largely based on trials in the early 2000s of esa use in malignancy with high hemoglobin hgb targets and large esa doses to attain the targets. Subsequently, in may 2007, fda convened another odac meeting to reassess the safety and effectiveness of esas in patients with cancer. Erythropoietin analogs contain the identical amino acid sequence as naturally occurring erythropoietin, and have the same biological effect. Erythropoiesis stimulating agents esa are medications which stimulate the bone marrow to make red blood cells. Anemia is common in patients with acute neurological disorders and may be a cause of secondary insults.
Erythropoiesisstimulating agents esas have been used to manage anemia in chronic kidney disease. Benefits and risks in supportive care of cancer article pdf available in current oncology 15suppl 1. Application for erythropoietinstimulating agents world health. Treatment with esas that resulted in higher hemoglobin levels increased risks for stroke, worsening hypertension, and vascular access thrombosis more than strategies that resulted in lower hemoglobin levels. Erythropoietin and erythropoiesisstimulating agents. Erythropoietin epo is an amino acid glycoprotein hormone synthesized and secreted by interstitial cells to stimulate the production of red blood cells in the bone marrow in response to falling levels of oxygen in the tissues. The use of erythropoiesisstimulating agents in patients with ckd. Recombinant human erythropoietin rhuepo and other erythropoiesisstimulating agents esa were synthesized after the initial cloning of the human erythropoietin epo gene sequence discovered in 1985 and have provided an alternative to transfusion for increasing red blood cell mass and treating anemia. The use of erythropoiesisstimulating agents in patients. Unitedhealthcare medicare advantage policy guideline. Erythropoiesisstimulating agents esas are produced using recombinant dna technologies. Erythropoiesisstimulating agents esas have been used to manage anemia in chronic kidney disease ckd to reduce transfusion requirements and anemia symptoms.
Decision memo for erythropoiesis stimulating agents esas. February 16, 2010 erythropoiesisstimulating agents esas. The maximum dosage of erythropoietin should not exceed a total of 60,000 units per week 5. Erythropoiesis stimulating agents esas have been implicated in causing cancer progression. Are all erythropoiesisstimulating agents created equal. They work by increasing red blood cells in the blood.
20 33 156 194 840 231 1461 672 1262 572 1391 862 869 184 1007 845 1337 709 1218 169 1439 453 627 358 942 1417 393 119 1266